This impairment of the Mrp2-dependent biochemical barrier may have important consequences by leading to the tissue accumulation of toxic endogenous metabolites and xenobiotics, as well as by potentially affecting the bioavailability and safety of clinically relevant substrate drugs, under obesity-related pathological conditions. The gene discussed is ABCC2; the disease is obesity due to melanocortin 4 receptor deficiency.